




RealRate

PHARMACEUTICAL 2022

Relmada Therapeutics INC
Rank 141 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Relmada Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Relmada Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 106% points. The greatest weakness of Relmada Therapeutics INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is 352%, being 77% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	223,298
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,061
Liabilities, Non-Current	0
Other Assets	28
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-48
Other Revenues	0
Property and Equipment	0
Research and Development	90,622
Selling, General and Administrative Expense	35,082

Output Variable	Value in 1000 USD
Assets	223,326
Liabilities	15,061
Expenses	125,703
Revenues	0
Stockholders Equity	208,265
Net Income	-125,752
Comprehensive Net Income	-125,752
BaseVar	182,069
ECR before Limited Liability	275%
Economic Capital Ratio	352%